Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

5 Oct 2022

Abstract excerpt

Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian cancer with high fatality rates in advanced stages due to its chemoresistant properties. LGSOC is characterized by activation of MAPK signaling, and recent clinical trials indicate that the MEK inhibitor (MEKi) trametinib may be a good treatment option for a subset of patients. Understanding MEKi-resistance mechanisms and subsequent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Mechanisms and Therapy
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36198031
DOI: 10.1158/1535-7163.mct-22-0004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK InhibitionPMID 36198031Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilitySemantic proximity Read ↗

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypesSemantic proximity Read ↗

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.Semantic proximity Read ↗

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaSemantic proximity Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.